Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis
,
Abstract
Background and Objectives: Vaginal candidiasis is a common disease in women during their lifetime and occurs in diabetes patients, during pregnancy and oral contraceptives users. Although several antifungals are routinely used for treatment; however, vaginal candidiasis is a challenge for patients and gynecologists. The aim of the present study was to evaluate terbinafine (Lamisil) on Candida vaginitis versus clotrimazole.
Materials and Methods: In the present study women suspected to have vulvovaginal candidiasis were sampled and disease confirmed using direct smear and culture examination from vaginal discharge. Then, patients were randomly divided into two groups, the first group (32 cases) was treated with clotrimazole and the next (25 cases) with Lamisil. All patients were followed-up to three weeks of treatment and therapeutic effects of both antifungal were compared.
Results: Our results shows that 12 (37.5%) patients were completely treated with clotrimazole during two weeks and,6(18.8%) patients did not respond to drugs and were refereed for fluconazole therapy. Fourteen (43.8%) patients showed moderate response and clotrimazole therapy was extended for one more week. When Lamisil was administrated, 19 (76.0%) patients were completely treated with Lamisil in two weeks, and 1 (4.0%) of the patients did not respond to the drug and was refereed for fluconazole therapy. Five (20.0%) of our patients showed moderate response and Lamisil therapy was extended for one more week.
Conclusion: Our results show that vaginal cream, 1% Lamisil, could be suggested as a first-line treatment in vulvovaginal candidiasis.
Ehrstrom S, Yu A, Rylander E. Glucose in vaginal secretions before and after oral glucose tolerance testing in women with and without recurrent vulvovaginal candidiasis. Obstet Gynecol 2006; 108: 1432-1437.
Watson C, Calabretto H. Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. Australian New Zealand J Obstet Gynaecol 2007; 47:262-272.
Meyer H, Goettlicher S, Mendling W. Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy. Mycoses 2006; 49: 202-209.
Novikova N, Rodrigues A, Mårdh PA. Can the diagnosis of recurrent vulvovaginal candidosis be improved by use of vaginal lavage samples and cultures on chromogenic agar? Infect Dis Obstet Gynecol 2002; 10: 89-92.
Nyirjesy P, Peyton C, Velma Weitz M, Mathew L, Culhane JF. Causes of Chronic vaginitis, analysis of a prospective database of affected women. Obstet Gynecol 2006; 108: 1185-1191.
Mohanty S, Xess I, Hasan F, Kapil A, Mittal S, Tolosa JE. Prevalence and susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian J Med Res 2007; 126: 216-219.
Zarei Mahmoudabadi A, Najafyan M, Alidadi M.Clinical study of Candida vaginitis in Ahvaz, Iran and susceptibility of agents to topical antifungal. Pak J Med Sci 2010; 26: 607-610.
Aghamirian MR, Keshavarz D, Jahani HashemiH, Sadeghi Qazvini M. Agents associated with Candida vulvovaginitis in women referred to health centers in Qazvin. J Qazvin Uni Med 2007; 11: 35-39.
Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155-2162.
Ventolini G, Baggish MS, Walsh PM. Vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy. J Reprod Med 2006; 51: 475-478.
Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W. A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses 2006; 49: 471-475.
García Heredia M, García SD, Copolillo EF, Cora Eliseth M, Barata AD, Vay CA, et al. Prevalence of vaginal candidiasis in pregnant women. Identification of yeasts and susceptibility to antifungal agents. Rev Argent Microbiol 2006; 38: 9-12.
Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J Microbiol 2011; 3: 183-188.
Shivakumar V, Okade R, Rajkumar V, Sajitha K, Prasad SR. Intermittent pulse-dosed terbinafine in the treatment of tinea corporis and/or tinea cruris. Indian J Dermatol 2011; 56: 121-122.
Gupta AK, Paquet M, Simpson F, Tavakkol A.
Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. J Eur Acad Dermatol Venereol 2012 May 28. doi: 10.1111/j.1468-3083.2012.04584.x. (Epub ahead of print)
López-Martínez R. Candidosis, a new challenge. Clin Dermatol 2010; 28: 178-184.
Gianni C. Update on antifungal therapy with terbinafine.G Ital Dermatol Venereol 2010; 145: 415-424.
Szigeti G, Sedaghati E, Zarei Mahmoudabadi A, Naseri A, Kocsubé S, Vágvölgyi C, Varga J. Species assignment and antifungal susceptibilities of black aspergilli recovered from otomycosis cases in Iran.
Mycoses 2012; 55: 333-338.
Jamilian M, Mashadi E, Sarmadi F, Ghaznavi A, Bani Jamali M, Farhadi E, et al. Frequency of vulvovaginal candidiasis species in non-pregnant 15-50 years old women in spring 2005 in Arak. J Arak Uni Med Sci 2007; 2: 7-14.
Us E, Cengiz SA. Prevalence and phenotypic evaluation of Candida dubliniensis in pregnant women with vulvovaginal candidosis in a university hospital in Ankara. Mycoses 2006; 50: 13-20.
Aali BS, Tohidi A. Prevalence of Candida vaginitis among symptomatic patients in Kerman. J Qazvin Uni Med Sci 2000; 13: 48-42.
Khorsandi M, Modares Gilani M, Khosravi AR.Recovery and recurrence of vaginal candidiasis after oral and intravaginal treatment. J Qazvin Uni Med Sci 2000; 14: 25-29.
Cernicka J, Subik J. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006; 7:403-408.
Ferahbas A, Koc AN, Uksal U, Aygen E, Mistik S, Yildiz S. Terbinafine versus itraconazole and fluconazole in the treatment of vulvovaginal candidiasis. Am J Ther 2006; 13: 332-336.
| Files | ||
| Issue | Vol 5 No 1 (2013) | |
| Section | Articles | |
| Keywords | ||
| Candida albicans Clotrimazole Terbinafine Vulvovaginal candidiasis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
